Literature DB >> 34559414

1,2,3-Triazole hybrids as anticancer agents: A review.

Mohammad Mahboob Alam1.   

Abstract

Despite the advancements in the development of anticancer agents, more effective and safer anticancer drugs still need to be developed as the current agents cause unwanted side effects and many patients have become drug resistant. 1,2,3-Triazoles, due to their remarkable biological potential, have received considerable attention in drug discovery for the development of anticancer agents. The present review article presents an overview of the recent advances in 1,2,3-triazole hybrids with anticancer potential over the last 2 years, their chemical structures, structure-activity relationships, and mechanisms of action, as well as insights into the docking studies.
© 2021 Deutsche Pharmazeutische Gesellschaft.

Entities:  

Keywords:  1,2,3-triazole; cancer; mechanism of action; structure-activity relationship

Mesh:

Substances:

Year:  2021        PMID: 34559414     DOI: 10.1002/ardp.202100158

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN: 0365-6233            Impact factor:   3.751


  4 in total

Review 1.  Structure-Activity Relationship of Benzofuran Derivatives with Potential Anticancer Activity.

Authors:  Joviana Farhat; Lara Alzyoud; Mohammad Alwahsh; Basem Al-Omari
Journal:  Cancers (Basel)       Date:  2022-04-28       Impact factor: 6.575

2.  New 1,2,3-triazole linked ciprofloxacin-chalcones induce DNA damage by inhibiting human topoisomerase I& II and tubulin polymerization.

Authors:  Hamada H H Mohammed; Amer Ali Abd El-Hafeez; Kareem Ebeid; Aml I Mekkawy; Mohammed A S Abourehab; Emad I Wafa; Suhaila O Alhaj-Suliman; Aliasger K Salem; Pradipta Ghosh; Gamal El-Din A Abuo-Rahma; Alaa M Hayallah; Samar H Abbas
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

3.  Green Synthesis and Anticancer Potential of 1,4-Dihydropyridines-Based Triazole Derivatives: In Silico and In Vitro Study.

Authors:  Sabera Bijani; Danish Iqbal; Sheefa Mirza; Vicky Jain; Sadaf Jahan; Mohammed Alsaweed; Yahya Madkhali; Suliman A Alsagaby; Saeed Banawas; Abdulrahman Algarni; Faris Alrumaihi; Rakesh M Rawal; Wael Alturaiki; Anamik Shah
Journal:  Life (Basel)       Date:  2022-03-31

4.  Design and synthesis of new bis(1,2,4-triazolo[3,4-b][1,3,4]thiadiazines) and bis((quinoxalin-2-yl)phenoxy)alkanes as anti-breast cancer agents through dual PARP-1 and EGFR targets inhibition.

Authors:  Fatma M Thabet; Kamal M Dawood; Eman A Ragab; Mohamed S Nafie; Ashraf A Abbas
Journal:  RSC Adv       Date:  2022-08-19       Impact factor: 4.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.